Previsión

El precio objetivo medio de los analistas es de +19,00€ (+35,81%). La mediana es de +17,60€ (+25,80%).

Comprar	10
Mantener	2
Vender	0

Noticias Ir al feed de noticias

Immunic appoints Elena Ridloff to the board of directors

Immunic has appointed Elena Ridloff to the board of directors with immediate effect. Ridloff brings more than 20 years of experience in finance, corporate development and capital markets in the biopharma industry, currently serving as CFO of Sionna Therapeutics and as a board member at Kymera Therapeutics. The appointment comes ahead of the expected top-line data from the phase-3 trials of Vidofludimus-Calcium in relapsing multiple sclerosis and before the planned initiation of a confirmatory phase-3 program for progressive MS. » Más en de.investing.com
Immunic appoints former Genentech exec Erik Lundgren as CEO

Immunic named Erik Lundgren CEO effective May 22, 2026, with his employment starting June 1; he succeeds Daniel Vitt who will remain on the board and continue to oversee scientific strategy and portfolio advancement. Lundgren brings nearly two decades of commercial and multiple sclerosis experience from Genentech and Roche, including work on the launch of Ocrevus. He will lead advancement of vidofludimus calcium through the pivotal phase 3 ENSURE trial in relapsing MS, a planned phase 3 program in primary progressive MS, and preparations for regulatory filings and potential commercialization. The company granted Lundgren an equity option to purchase 1 million shares under its 2026 inducement plan. » Más en finance.yahoo.com
Immunic records loss per share of $1.08 in last quarter

Immunic released its quarterly results on May 13, 2026, reporting a loss per share of $1.08. In the year-ago period the loss was $2.50 per share. » Más en finanzen.net

Datos financieros de la empresa

En el último trimestre, Immunic tuvo unos ingresos de 0,00€ y un beneficio neto de −29,88M€

(EUR)	jun 2026	YoY
Ingresos	0,00	-
Beneficio bruto	0,00	-
Beneficio neto	−29,88M	31,30%
EBITDA	−29,79M	31,13%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+191,99M€
Número de acciones	13,62M
Máximo/mínimo de 52 semanas	+14,96€ - +4,34€
Dividendos	No
Beta	1,4
Ratio P/E	−3,42
Ratio PEG	−0,04
Ratio P/B	+5,47
Ratio P/S	0,00

Perfil de la empresa

Immunic, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt eine Pipeline selektiver oraler immunologischer Therapien zur Behandlung chronischer Entzündungs- und Autoimmunerkrankungen. Sein führendes Entwicklungsprogramm ist IMU-838, das sich in der klinischen Phase 2 zur Behandlung von schubförmig remittierender Multipler Sklerose, entzündlichen Darmerkrankungen und anderen chronischen Entzündungs- und Autoimmunerkrankungen sowie zur Behandlung von Coronaviruserkrankungen befindet. Das Unternehmen entwickelt außerdem IMU-935, einen inversen Agonisten von ROR?t, und IMU-856 zur Wiederherstellung der Darmbarrierefunktion bei Patienten, die an Krankheiten wie entzündlichen Darmerkrankungen, Reizdarmsyndrom mit Durchfall, durch Immun-Checkpoint-Inhibitoren ausgelöster Kolitis und anderen Erkrankungen der Darmbarrierefunktion leiden. Der Hauptsitz von Immunic, Inc. befindet sich in New York, New York.

Nombre	Immunic
CEO	Erik Lundgren
Sede	New York City, ny Estados Unidos
Sitio web	immunic-therapeutics.com
Sector	Salud
Industria	Biotecnología
Salida a bolsa	17/04/2014
Empleados	95